NuCana BioMed Ltd, a Scotland-based company with a portfolio of anti-cancer medicines, has announced the appointment of Professor Chris McGuigan as chief scientific officer. Prof McGuigan is the inventor of ProTide technology, which describes compounds with a protective phosphoramidate group which can reportedly bypass tumour resistance mechanisms. NuCana’s lead product is based on this technology.
The new CSO is currently professor of medicinal chemistry at the Cardiff School of Pharmacy and Pharmaceutical Sciences and chair of the Life Sciences Hub Wales.
NuCana announced the appointment on 1 July 2015.
Copyright 2015 Evernow Publishing Ltd